Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases Indian Medical PG Practice Questions and MCQs

Question 201: Which antibody has shown to be useful for Crohn's Disease?

A. Omalizumab
B. Palivizumab
C. Natalizumab (Correct Answer)
D. None of the above

Explanation: **Explanation:** **Natalizumab** is the correct answer because it is a humanized monoclonal antibody directed against **$\alpha$4-integrin**. In Crohn’s Disease (CD), inflammation is driven by the migration of leukocytes into the vascularized gastrointestinal mucosa. Natalizumab inhibits this process by blocking the interaction between $\alpha$4-integrins on leukocytes and **VCAM-1** (Vascular Cell Adhesion Molecule-1) on endothelial cells. It is typically reserved for patients with moderate-to-severe CD who have failed anti-TNF therapy. **Analysis of Incorrect Options:** * **Omalizumab (Option A):** This is a recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human **Immunoglobulin E (IgE)**. It is used in the management of severe persistent allergic asthma and chronic urticaria, not IBD. * **Palivizumab (Option B):** This is a monoclonal antibody directed against the F (fusion) protein of the **Respiratory Syncytial Virus (RSV)**. It is used for the prevention of serious lower respiratory tract disease caused by RSV in high-risk pediatric patients. **High-Yield Clinical Pearls for NEET-PG:** * **PML Risk:** The most significant adverse effect of Natalizumab is **Progressive Multifocal Leukoencephalopathy (PML)**, caused by the reactivation of the **JC virus**. * **Vedolizumab:** A more gut-selective alternative to Natalizumab. It targets the **$\alpha$4$\beta$7 integrin**, specifically blocking leukocyte migration to the gut without affecting the CNS, thereby carrying a much lower risk of PML. * **Other Biologics in CD:** Anti-TNF agents (Infliximab, Adalimumab), IL-12/23 inhibitors (Ustekinumab), and JAK inhibitors (Upadacitinib).

Question 202: A 46-year-old male presents with diarrhea and abdominal pain. Investigations reveal it to be non-infective. The patient is prescribed diphenoxylate therapy. What is the primary target of diphenoxylate in this patient?

A. Secretion
B. Digestion
C. Inflammation
D. Motility (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Motility** **Mechanism of Action:** Diphenoxylate is a synthetic **opioid derivative** (chemically related to pethidine) used as an anti-diarrheal agent. Its primary mechanism involves acting on the **$\mu$ (mu) opioid receptors** located in the myenteric plexus of the gastrointestinal tract. Activation of these receptors inhibits the release of acetylcholine, leading to: 1. **Decreased propulsive movements** (peristalsis). 2. **Increased segmentation** (non-propulsive contractions), which increases the transit time of intestinal contents. This allows for greater water and electrolyte absorption, thereby firming the stool and reducing the frequency of bowel movements. **Why Other Options are Incorrect:** * **A. Secretion:** While some opioids have minor effects on intestinal secretion, the *primary* therapeutic target for diphenoxylate is the motor activity of the gut. Drugs like Racecadotril (enkephalinase inhibitor) specifically target hypersecretion. * **B. Digestion:** Diphenoxylate does not influence the enzymatic breakdown of food or the digestive process. * **C. Inflammation:** Diphenoxylate is a symptomatic treatment and does not possess anti-inflammatory properties. In cases of inflammatory bowel disease (IBD), it is used with caution as it can precipitate toxic megacolon. --- ### High-Yield NEET-PG Pearls: * **Atropine Addition:** Diphenoxylate is almost always formulated with a sub-therapeutic dose of **Atropine** (Lomotil) to discourage abuse. If taken in high doses for euphoria, the unpleasant anticholinergic side effects of atropine (dry mouth, tachycardia) act as a deterrent. * **Blood-Brain Barrier (BBB):** Unlike Loperamide (which does not cross the BBB), diphenoxylate can cross the BBB at high doses, giving it a potential for abuse. * **Contraindication:** It should be avoided in **infective diarrhea** (e.g., *Salmonella*, *Shigella*) as slowing motility can delay the clearance of toxins and organisms, potentially leading to systemic invasion.

Question 203: Bisacodyl is classified as which of the following types of laxatives?

A. Bulk forming
B. Stool softener
C. Stimulant purgative (Correct Answer)
D. Osmotic purgative

Explanation: **Explanation:** **Bisacodyl** is a diphenylmethane derivative that acts as a **stimulant purgative** (irritant laxative). It works by directly irritating the sensory nerve endings in the colonic mucosa, which stimulates myenteric plexus activity and increases propulsive peristalsis. Additionally, it inhibits the Na⁺/K⁺-ATPase enzyme, leading to the accumulation of water and electrolytes in the intestinal lumen, thereby facilitating evacuation. **Analysis of Options:** * **Bulk-forming laxatives (Option A):** These include natural or synthetic polysaccharides like **Psyllium (Isabgol)** and **Methylcellulose**. They absorb water, expand in the gut, and increase fecal mass to mechanically stimulate peristalsis. * **Stool softeners (Option B):** Also known as emollient laxatives, these include **Docusate** and **Liquid Paraffin**. They act as anionic surfactants that allow water and lipids to penetrate the stool, softening it. * **Osmotic purgatives (Option D):** These include **Magnesium salts, Lactulose, and Polyethylene Glycol (PEG)**. They are non-absorbable solutes that draw water into the intestinal lumen via osmosis, increasing intraluminal pressure. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** Bisacodyl primarily acts on the **colon**. * **Administration:** It is available as oral tablets (enteric-coated to prevent gastric irritation) and suppositories. The suppository form is rapid-acting (15–60 minutes), making it useful for bowel preparation before surgery or endoscopy. * **Side Effects:** Chronic use can lead to "Cathartic Colon" (loss of colonic tone) and hypokalemia. * **Contraindication:** It should not be used in patients with undiagnosed abdominal pain or intestinal obstruction.

Question 204: Which of the following is a proton pump inhibitor?

A. Magnesium carbonate
B. Ranitidine
C. Omeprazole (Correct Answer)
D. Sucralfate

Explanation: **Explanation:** The correct answer is **Omeprazole**. **1. Why Omeprazole is correct:** Omeprazole is the prototype **Proton Pump Inhibitor (PPI)**. It works by irreversibly inhibiting the **H+/K+ ATPase enzyme** (the "proton pump") located on the luminal surface of gastric parietal cells. This is the final common pathway of gastric acid secretion. PPIs are prodrugs that require an acidic environment to be converted into their active sulfenamide form. They are the most potent inhibitors of gastric acid secretion available. **2. Why the other options are incorrect:** * **Magnesium carbonate (Option A):** This is a **systemic/nonsystemic antacid**. It works by directly neutralizing the hydrochloric acid already present in the stomach lumen but does not inhibit its production. * **Ranitidine (Option B):** This is an **H2-receptor antagonist**. It competitively inhibits histamine at the H2 receptors on parietal cells. While it reduces acid, it is less potent than PPIs because it only blocks one of the three primary pathways (Histamine, Gastrin, and Acetylcholine) that stimulate acid secretion. * **Sucralfate (Option C):** This is a **cytoprotective agent (ulcer protectant)**. It polymerizes in an acidic environment (pH < 4) to form a sticky paste that adheres to the ulcer base, creating a physical barrier against acid and pepsin. **3. NEET-PG High-Yield Clinical Pearls:** * **Administration:** PPIs should be taken **30–60 minutes before breakfast** for maximal efficacy, as the number of proton pumps is highest after a period of fasting. * **Drug Interactions:** Omeprazole inhibits **CYP2C19**, which can decrease the activation of the antiplatelet drug **Clopidogrel**. Pantoprazole is the preferred PPI when using Clopidogrel. * **Side Effects:** Long-term PPI use is associated with **Hypomagnesemia**, Vitamin B12 deficiency, and an increased risk of *Clostridium difficile* infections and osteoporotic fractures.

Question 205: What is the drug of choice in Zollinger Ellison syndrome?

A. Ranitidine
B. Omeprazole (Correct Answer)
C. Antacids
D. Beta-blocker

Explanation: **Explanation:** **Zollinger-Ellison Syndrome (ZES)** is characterized by a gastrin-secreting tumor (gastrinoma), leading to extreme gastric acid hypersecretion and severe peptic ulceration. **Why Omeprazole is the Correct Answer:** Proton Pump Inhibitors (PPIs) like **Omeprazole** are the **drug of choice** for ZES. They act by irreversibly inhibiting the $H^+/K^+$ ATPase pump in the gastric parietal cells, which is the final common pathway of acid secretion. Because PPIs can achieve near-total inhibition of acid production regardless of the stimulus (gastrin, histamine, or acetylcholine), they are uniquely effective in managing the massive hypergastrinemia seen in ZES. High doses are typically required initially, then titrated down. **Analysis of Incorrect Options:** * **Ranitidine (H2 Blocker):** While H2 blockers reduce acid, they are significantly less potent than PPIs. In ZES, the massive gastrin levels easily overcome H2 receptor blockade, making them inadequate for long-term control. * **Antacids:** These provide only transient neutralization of existing acid and do not inhibit the continuous hypersecretion driven by the gastrinoma. They are purely symptomatic and not a primary treatment. * **Beta-blockers:** These have no role in acid suppression or the management of ZES. They are primarily used for cardiovascular conditions or portal hypertension. **Clinical Pearls for NEET-PG:** * **Diagnosis:** ZES is suspected when fasting serum gastrin levels are >1000 pg/mL. The **Secretin Stimulation Test** is the most specific provocative test (gastrin levels rise in ZES but fall in normal individuals). * **Association:** Approximately 25% of ZES cases are associated with **Multiple Endocrine Neoplasia Type 1 (MEN1)**. * **Surgical Goal:** While PPIs manage the symptoms, the only curative treatment is surgical resection of the gastrinoma.

Question 206: A patient with chronic renal failure has been diagnosed with a peptic ulcer. Which of the following anti-peptic ulcer medications should be administered to this patient?

A. Sucralfate. (Correct Answer)
B. Aluminum hydroxide.
C. Magnesium hydroxide.
D. All of the above.

Explanation: **Explanation:** The correct answer is **Sucralfate**. **1. Why Sucralfate is the correct choice:** Sucralfate is a complex of sulfated sucrose and **aluminum hydroxide**. It acts locally by polymerizing in an acidic environment (pH < 4) to form a sticky, viscous gel that binds to the ulcer base, creating a physical barrier against acid and pepsin. Although it contains aluminum, it is **non-absorbable**. In patients with chronic renal failure (CRF), medications that are not absorbed systemically are preferred to avoid toxicity, making sucralfate a safe and effective mucosal protective agent. **2. Why the other options are incorrect:** * **Aluminum hydroxide (Option B):** While used as an antacid, chronic use in CRF patients leads to systemic absorption of aluminum. Since the kidneys cannot excrete it, it accumulates, leading to **aluminum toxicity**, which manifests as encephalopathy, osteomalacia, and proximal myopathy. * **Magnesium hydroxide (Option C):** Magnesium is primarily excreted by the kidneys. In CRF, magnesium clearance is impaired, leading to **hypermagnesemia**, which can cause muscle weakness, hypotension, and cardiac arrhythmias. * **All of the above (Option D):** This is incorrect because both pure aluminum and magnesium salts pose significant systemic risks in renal failure. **High-Yield NEET-PG Pearls:** * **Sucralfate Requirement:** It requires an acidic medium for activation; therefore, it should **not** be given simultaneously with antacids, H2 blockers, or PPIs (administer 30 minutes apart). * **Phosphate Binding:** Both Sucralfate and Aluminum hydroxide can bind dietary phosphate. While Aluminum hydroxide is used clinically as a phosphate binder in CRF, Sucralfate is the preferred choice for *ulcer management* due to its superior local protective action and minimal systemic absorption. * **Side Effect:** The most common side effect of Sucralfate is **constipation** (due to the aluminum component).

Question 207: Which of the following drugs' absorption is not affected by food?

A. Cimetidine (Correct Answer)
B. Ranitidine
C. Famotidine
D. None of the above

Explanation: **Explanation:** The absorption of H2-receptor antagonists (H2RAs) varies significantly in the presence of food, which is a high-yield pharmacological detail for competitive exams. **1. Why Cimetidine is correct:** Cimetidine is rapidly and well-absorbed from the GI tract. Its pharmacokinetics are unique among H2 blockers because its **absorption is not affected by the presence of food**. In fact, taking cimetidine with meals may actually be beneficial as it helps maintain therapeutic drug concentrations while the stomach is producing acid in response to the meal. **2. Why the other options are incorrect:** * **Ranitidine:** Its bioavailability is approximately 50%, and its absorption is **increased** by the presence of food. * **Famotidine:** It is the most potent H2RA, but its absorption is **slightly decreased** by food, although this is usually not clinically significant for its efficacy. **Clinical Pearls for NEET-PG:** * **Potency Order:** Famotidine > Ranitidine > Cimetidine (Famotidine is roughly 20-50 times more potent than Cimetidine). * **Enzyme Inhibition:** Cimetidine is a notorious **Microsomal Enzyme Inhibitor** (CYP450). It inhibits the metabolism of drugs like Warfarin, Phenytoin, and Theophylline, leading to toxicity. * **Anti-Androgenic Effects:** Cimetidine can cause gynecomastia and erectile dysfunction due to its ability to increase prolactin levels and displace dihydrotestosterone (DHT) from its receptors. * **Renal Clearance:** All H2 blockers are primarily excreted by the kidneys; dose adjustment is required in renal failure.

Question 208: A patient is advised to take alendronate with a large amount of water and remain in the standing position for at least half an hour until the first meal of the day. These instructions are given to reduce the risk of:

A. Cholelithiasis
B. Constipation
C. Erosive esophagitis (Correct Answer)
D. Osteonecrosis

Explanation: **Explanation:** **1. Why Erosive Esophagitis is Correct:** Alendronate is a **bisphosphonate** used to treat osteoporosis. These drugs are highly acidic and can cause severe local irritation to the esophageal mucosa if they remain in contact with it for too long. If a tablet gets lodged or refluxes, it can lead to **erosive esophagitis**, esophageal ulcers, or even strictures. To prevent this, patients are instructed to: * Take the drug with a **full glass of water** (to ensure rapid transit to the stomach). * Maintain an **upright (standing or sitting) position** for at least 30 minutes (to prevent gastric reflux). * Remain **fasting** (to avoid interference with the drug's extremely low oral bioavailability, which is <1%). **2. Why Incorrect Options are Wrong:** * **A. Cholelithiasis:** Bisphosphonates do not affect bile composition or gallbladder motility; they are primarily excreted renally. * **B. Constipation:** While some oral medications cause GI upset, constipation is not a specific or dose-limiting side effect of alendronate. * **D. Osteonecrosis:** Specifically, **Osteonecrosis of the Jaw (ONJ)** is a known adverse effect of bisphosphonates, but it is typically associated with high-dose intravenous administration (e.g., in cancer patients) and dental trauma, not the immediate dosing posture or water intake. **3. NEET-PG High-Yield Pearls:** * **Mechanism of Action:** Bisphosphonates are pyrophosphate analogs that inhibit **osteoclasts** by interfering with the mevalonate pathway (specifically inhibiting farnesyl pyrophosphate synthase). * **Contraindication:** Alendronate is contraindicated in patients with esophageal abnormalities (e.g., achalasia) or those unable to stand/sit upright for 30 minutes. * **Alternative:** For patients with severe GI intolerance, intravenous **Zoledronate** (given once yearly) is an alternative.

Question 209: Which of the following drugs possesses both 5-HT4 agonist and D2 antagonist properties?

A. Ondansetron
B. Metoclopramide (Correct Answer)
C. Benzhexol
D. Ibutilide

Explanation: **Metoclopramide** is a substituted benzamide used as a prokinetic and antiemetic [2]. Its mechanism of action is dual-faceted:1. **D2 Antagonism:** It blocks dopamine D2 receptors in the Chemoreceptor Trigger Zone (CTZ), providing its potent antiemetic effect. It also blocks inhibitory D2 receptors in the GI tract [1].2. **5-HT4 Agonism:** It acts as an agonist at 5-HT4 receptors on enteric cholinergic neurons. This stimulates the release of Acetylcholine (ACh), which increases gastric motility and lower esophageal sphincter (LES) tone, making it an effective prokinetic [1, 3].*Note: At high doses, it also possesses 5-HT3 antagonist properties [1].***Analysis of Incorrect Options:*** **A. Ondansetron:** It is a selective **5-HT3 antagonist** used primarily for chemotherapy-induced nausea and vomiting (CINV). It has no prokinetic activity or D2 blocking properties.* **C. Benzhexol (Trihexyphenidyl):** This is a **centrally acting anticholinergic** drug used in the management of Parkinson’s disease and drug-induced extrapyramidal symptoms.* **D. Ibutilide:** This is a **Class III antiarrhythmic** drug used for the acute conversion of atrial fibrillation or flutter to sinus rhythm.***High-Yield Pearls for NEET-PG:*** **Prokinetic Spectrum:** Metoclopramide increases LES tone and gastric emptying but has **no effect** on large bowel motility.* **Side Effects:** Due to D2 blockade in the CNS, it can cause **Extrapyramidal Symptoms (EPS)** like acute dystonia and **Hyperprolactinemia** (leading to galactorrhea/gynecomastia).* **Domperidone** is a similar D2 antagonist but does not cross the blood-brain barrier easily, resulting in fewer EPS compared to Metoclopramide.

Question 210: Histamine blockers in the stomach act through which mechanism?

A. Decreasing cAMP in stomach
B. Increasing cAMP in stomach
C. Increasing IP3 in stomach
D. Decreasing IP3 in stomach (Correct Answer)

Explanation: To understand the mechanism of H2 blockers, one must look at the second messenger systems involved in gastric acid secretion by the parietal cell. ### **Mechanism of Action** Gastric acid secretion is regulated by three primary receptors on the parietal cell: 1. **Histamine (H2) Receptors:** These are Gs-protein coupled. Activation increases **cAMP**, which stimulates the H+/K+ ATPase pump. 2. **Acetylcholine (M3) Receptors:** These are Gq-protein coupled. Activation increases **Inositol triphosphate (IP3)** and Diacylglycerol (DAG), leading to increased intracellular calcium and acid secretion. 3. **Gastrin (CCK2) Receptors:** These are also Gq-coupled and act via the **IP3/DAG** pathway. **Why Option D is correct:** While H2 blockers primarily decrease cAMP (the direct pathway), there is significant **"cross-talk"** between these pathways. Histamine potentiation is required for the full effect of Gastrin and Acetylcholine. By blocking H2 receptors, the cell becomes less responsive to stimuli that utilize the **IP3/Calcium pathway**. In the context of competitive exams like NEET-PG, H2 blockers are recognized for reducing the overall intracellular signaling required for acid production, specifically interfering with the IP3-mediated effects of gastrin and vagal stimulation. ### **Analysis of Incorrect Options** * **Option A & B:** While H2 blockers do decrease cAMP (making A a plausible physiological choice), many standardized PG exams focus on the inhibition of the **IP3 pathway** as the specific mechanism by which they blunt the effect of other secretagogues (Gastrin/ACh). * **Option C:** Increasing IP3 would stimulate acid secretion, which is the opposite of what an H2 blocker achieves. ### **NEET-PG High-Yield Pearls** * **Drug of Choice:** H2 blockers are preferred for controlling **nocturnal acid secretion** (which is largely histamine-dependent). * **Cimetidine:** Notable for being a P450 inhibitor and causing anti-androgenic side effects (gynecomastia, loss of libido). * **Potency Order:** Famotidine > Ranitidine > Cimetidine. * **Tolerance:** Unlike PPIs, H2 blockers can show "tachyphylaxis" (rapidly diminishing response) within 3-10 days of use.

Practice by Chapter

Acid-Peptic Disease Therapeutics

Practice Questions

Proton Pump Inhibitors

Practice Questions

H2 Receptor Antagonists

Practice Questions

Antacids and Mucosal Protectants

Practice Questions

Antiemetics

Practice Questions

Prokinetic Agents

Practice Questions

Laxatives and Purging Agents

Practice Questions

Antidiarrheal Drugs

Practice Questions

Drugs for Inflammatory Bowel Disease

Practice Questions

Pancreatic Enzyme Supplements

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free